Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer.

Cancer cytopathology - 1 Sept 2021

Amemiya Kenji, Hirotsu Yosuke, Nagakubo Yuki, Mochizuki Hitoshi, Higuchi Rumi, Tsutsui Toshiharu, Kakizaki Yumiko, Miyashita Yoshihiro, Oyama Toshio, Omata Masao

Abstract excerpt

BACKGROUND: Molecular testing is critical for identifying actionable variants in lung cancer for precision medicine. When tumor tissue samples are unavailable, archived cytological specimens (ACSs) can be used. The authors examined whether oncogenic variants could be accurately detected in ACSs versus paired formalin-fixed, paraffin-embedded (FFPE) tumor tissues with in vitro diagnostic tests. METHODS: The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Fusion
Share to Diagnostic Tests, Routine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Proto-Oncogene Proteins

Share to Proto-Oncogene Proteins B-raf

Share to RNA, Neoplasm

Source

Identifiers

PMID: 33872472
DOI: 10.1002/cncy.22434

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Actionable driver DNA variants and fusion genes can be detected in archived cytological specimens with the Oncomine Dx Target Test Multi-CDx system in lung cancer.PMID 33872472Read ↗

Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer.Semantic proximity Read ↗

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.Semantic proximity Read ↗

Genome analysis of peeling archival cytology samples detects driver mutations in lung cancer.Semantic proximity Read ↗

Detection of Multiple Types of Cancer Driver Mutations Using Targeted RNA Sequencing in NSCLCSemantic proximity Read ↗

Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patientsSemantic proximity Read ↗

Liquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinomaSemantic proximity Read ↗

Precision medicine and actionable alterations in lung cancer: A single institution experience.Semantic proximity Read ↗

Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencerSemantic proximity Read ↗

High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.Semantic proximity Read ↗

Targeted RNA sequencing for upfront analysis of actionable driver alterations in non-small cell lung cancer.Semantic proximity Read ↗

Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer.Semantic proximity Read ↗

Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLCSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.